2025 Volume 14 Issue 2 Pages 91-96
Recent advancements in novel drugs and diagnostic technologies have significantly improved leukemia treatment, leading to ongoing changes in treatment strategies. It has become clear that some types of leukemia, previously considered difficult to cure without allogeneic hematopoietic stem cell transplantation, can now be treated without transplantation. However, there are still leukemias that relapse or become refractory despite various therapeutic approaches, which remains a major challenge for hematologists. For high-relapse-risk leukemia, cord blood transplantation (CBT), which can be rapidly and reliably prepared and is expected to offer a strong graft-versus-leukemia effect (GVL) due to pre-engraftment immune reaction (PIR), combined with maintenance therapy aimed at preventing relapse, holds great potential. These advances are expected to represent a significant step forward in overcoming high-relapse-risk leukemia.
